Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immutep ADS Representing 10 Ord Shs IMMP

Healthcare Biotechnology
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to... see more

Recent & Breaking News (NDAQ:IMMP)

Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

GlobeNewswire January 21, 2021

Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study

GlobeNewswire January 6, 2021

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

GlobeNewswire December 29, 2020

Immutep Upscales Efti Manufacturing

GlobeNewswire December 16, 2020

Immutep Operational Update

GlobeNewswire December 15, 2020

Immutep's Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study

GlobeNewswire December 9, 2020

Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer

GlobeNewswire December 9, 2020

Immutep Announces Expansion of TACTI-002 Collaboration Trial

GlobeNewswire November 18, 2020

Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development

GlobeNewswire November 18, 2020

Immutep's Phase II TACTI-002 Study Reports Encouraging Data at SITC

GlobeNewswire November 9, 2020

Immutep Announces Australian Patent Grant For IMP701 Antibody

GlobeNewswire November 9, 2020

Immutep's TACTI-002 Data to Be Presented at Society for Immunotherapy of Cancer 2020 Annual Meeting

GlobeNewswire November 2, 2020

Immutep to Collaborate with LabCorp to Develop Oncology Services and Products

GlobeNewswire October 29, 2020

Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

GlobeNewswire October 23, 2020

Immutep Activities Report for the First Quarter of Fiscal Year 2021

GlobeNewswire October 21, 2020

Immutep Granted European Patent for IMP761

GlobeNewswire October 21, 2020

Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020

GlobeNewswire October 19, 2020

Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

GlobeNewswire September 17, 2020

Immutep Reports Improving Results from INSIGHT-004 Trial

GlobeNewswire September 17, 2020

Immutep and Monash University Receive Grant Funding for LAG-3 Project

GlobeNewswire August 31, 2020